Literature DB >> 16080417

Using return on equity and total profit margin to evaluate hospital performance in the U.S.: a piecewise regression analysis.

Mustafa Z Younis1, Dana A Forgione.   

Abstract

We investigated hospital profitability by comparing Total Profit Margin (TPM) and Return on Equity (ROE) as measures of profitability, while controlling for inflation and other salient factors. We controlled for variables such as, Disproportionate Share Hospital status, location, type of ownership control, teaching status, conversion to or from nonprofit status, Critical Access Hospital status, sole Medicare provider status, case mix adjusted patient length of stay, bed size, number of employees, and occupancy rate. We allowed for nonlinearities in our model, and used 1996 and 1998 data in our analysis to bridge potential effects of the Balanced Budget Act of 1997. Most of the hospitals we examined were nonprofit organizations that did not convert their type of ownership control. As a consequence, we found TPM to be a better measure of profitability than ROE, and profitability was mainly influenced by location, size, occupancy rate, volume of Medicare and Medicaid patients, and teaching status. Our results clarify the primary factors associated with profitability for our sample hospitals, and will assist creditors, managers and regulators in their assessments of comparative hospital financial performance.

Entities:  

Mesh:

Year:  2005        PMID: 16080417

Source DB:  PubMed          Journal:  J Health Care Finance        ISSN: 1078-6767


  2 in total

1.  A Decomposition of Hospital Profitability: An Application of DuPont Analysis to the US Market.

Authors:  Jason Turner; Kevin Broom; Michael Elliott; Jen-Fu Lee
Journal:  Health Serv Res Manag Epidemiol       Date:  2015-07-22

2.  The relationship between safety net activities and hospital financial performance.

Authors:  Jack Zwanziger; Nasreen Khan; Anil Bamezai
Journal:  BMC Health Serv Res       Date:  2010-01-14       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.